NCT06239727 2026-03-06
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
17 trialsNCT06976190 2026-01-20
Magic-C002
Shanghai Miracogen Inc.
Phase 3 Recruiting
NCT07248670 2025-11-25
Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC
Chongqing University Cancer Hospital
Phase 3 Active not recruiting
NCT06118333 2025-09-30
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06629597 2025-02-10
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Recruiting
NCT05869227 2024-12-30
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT06277050 2024-04-30
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
Jiangxi Provincial Cancer Hospital
Phase 3 Recruiting
NCT02940925 2023-04-12
TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT02460419 2022-10-28
Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT05342792 2022-04-25
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT00379262 2019-08-07
Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
Hong Kong Nasopharyngeal Cancer Study Group Limited
Phase 3 Completed
NCT02958111 2019-06-12
CAN
Sun Yat-sen University
Phase 3 Unknown
NCT03503136 2018-05-11
NX-NPC
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT02786641 2016-06-01
Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT02633176 2015-12-17
Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT02621970 2015-12-04
Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Unknown